Home / KEEP BUT DO NOT DISPLAY / Alerts (page 2)


Ordered by most recent

Afrezza Now Available in U.S.

Sanofi and MannKind have announced that their inhaled insulin powder, Afrezza, is now available in the U.S. The product is administered via a small, portable inhaler to help boost glucose control in diabetes patients.

Read More »

FDA Approves Empagliflozin/Linagliptin Combo (Glyxambi) for Type 2

The Boehringer Ingelheim/Eli Lilly and Company combination SGLT2 inhibitor and DPP-4 inhibitor Glyxambi has been approved by the FDA. The empagliflozin/linagliptin combo is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when neither of the individual components are working as …

Read More »

FDA Approves VBLOC Vagal Blocking Therapy for Weight Loss

VBLOC Therapy is a first-in-class weight loss treatment that addresses the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension. Therapy is delivered by a pacemaker-like device called the Maestro® Rechargeable System controls both hunger and fullness by blocking the primary nerve which regulates …

Read More »

FDA Approves Liraglutide (Saxenda) for Weight Loss

FDA Approves Liraglutide (Saxenda) for Weight Loss The U.S. Food and Drug Administration has approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. See this week’s Item 11. "The approval of Saxenda adds a unique tool …

Read More »